Who Optimizes SG&A Costs Better? Biogen Inc. or Exelixis, Inc.

Optimizing SG&A Costs: A Tale of Two Biotech Giants

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Biogen Inc. and Exelixis, Inc., two prominent players in the industry, have shown contrasting strategies over the past decade. From 2014 to 2023, Biogen's SG&A expenses have consistently been higher, peaking in 2021 with a 38% increase from 2014. In contrast, Exelixis, Inc. has demonstrated a more aggressive growth in SG&A, with a staggering 967% increase over the same period. This reflects Exelixis's rapid expansion and investment in administrative capabilities. While Biogen's expenses have remained relatively stable, Exelixis's rising costs suggest a strategic push towards growth. Understanding these trends offers valuable insights into how these companies navigate financial management in a dynamic market.